Global, Regional, and National Prevalence of Overweight and Obesity in Children and Adults during 19802013: A Systematic Analysis for the Global Burden of Disease Study 2013
Plus, Baker suspects that broader availability of GLP-1 medications through Hims & Hers and similar platforms such as Ro will drive down prices long-term, and may spur cost-offsetting programs to spring up to help meet demand
Yes, injection site selection does matter when administering glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), or liraglutide (Victoza, Saxenda)
Less BAC water = higher concentration = fewer units per dose (more practical for large doses, but precision decreases)
By influencing metabolic health and blood sugar regulation, they potentially support enhanced energy balance and body composition goals
To summarize the last article: GLP-1 medications are reshaping modern medicine because they target the gut-brain-metabolic axis that drives most chronic disease - not just weight loss, but cardiovascular disease, heart failure, kidney disease, neurodegeneration, fatty liver, and systemic inflammation
